Cystic Fibrosis Flashcards

1
Q

What is cystic fibrosis?

A
  • Autosomal recessive condition with up to 1000 different mutations in CFTR
  • One of the most common life-limiting genetic conditions in western world
  • Life expectancy 40 years
  • ∆F508 mutation- phenylalanine (main)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

What is CFTR?

A

cystic fibrosis transmembrane conductance regulator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What is normal CFTR?

A
  • Chloride expressed in epithelial cells throughout body

- Channel opening regulated by ATP binding to nucleotide binding domains and phosphorylation of regulatory domain

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Describe the processing of normal CFTR

A
  • Synthesised in endoplasmic reticulum
  • Chaperones facilitate correct folding
  • Transported to Golgi
  • Glycosylated
  • Inserted into membrane in inactive form
  • Activated by binding of ATP and phosphorylated of the regulated domain
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

How does CFTR function in bronchial epithelium?

A
  • transports 90% of Cl- ions
  • CRTR has a negative regulatory effect on epithelial sodium channel
  • Closes it so sodium cannot enter cell
  • Na+ comes in through airway lumen
  • Rapidly transported out of the base of cell
  • K+ enters when this happens
  • Na+/K+/Cl- co-transporter
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

What is the role of mucus in bronchial epithelium?

A
  • Thin layer of mucus with high elasticity and low viscosity traps pathogens and particulates
  • Movement from base of lung to glottis
  • Thin watery periciliary fluid supports mucus layer
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What can go wrong with CFTR?

A
  • Failure of CFTR can affect salt/water balance

- Results in production of large amounts of thick sticky mucus that are not cleared by muco-ciliary escalator

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How is ∆F508 CRTR processed?

A
  • Synthesised in endoplasmic reticulum
  • Loss of Phe509 means it does not fold correctly
  • Misfolded protein targeted for destruction in proteasome
  • No surface expression of CFTR and no Cl- movement
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is the effect of ∆F508 in CF bronchial epithelium?

A
  • No down regulation of sodium channel
  • Na+ flooding into cells
  • Increase in Na+/K+ ATPases to move Na+ out
  • Trying to maintain sodium levels
  • More ATP used to move Na+ out
  • Only a small mount of chloride moving out (alternative chloride channels)
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What are the consequences of ∆F508 on mucus production in the lung?

A
  • Mucus becomes thick and dessicated
  • Colonised with bacteria
  • Cilia compressed and fail to clear mucus
  • Water and salt absorbed into lung
  • Neutrophils recruited to combat bacterial infection
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

Why are neutrophils so damaging to the lung?

A
  • Large numbers of bacteria present in CF lung
  • Neutrophils fail to destroy them in the normal way
  • Frustrated phagocytosis
  • Results in release activates oxygen and neutrophil proteases into extracellular space where they damage lung tissue as well as bacteria
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
12
Q

What are the other types of CFTR defect (6 groups)?

A
  • 1- no synthesis of CFTR at all
  • 2- processing defect- not able to embed on surface
  • 3-regulatory defect- issue with opening and interacting
  • 4- altered conductance- issue with ion movement through channel
  • 5- reduced synthesis- not enough channels
  • 6- increased turnover, more quickly broken down
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What are the clinical problems in CF?

A
  • Diagnostic triad
  • Persistent chest infection (2-3 year old)- accumulation of mucus in airways
  • Failure to thrive- children fail to gain weight, increased metabolic demand
  • Salty sweat- 79mM as NaCl not reabsorbed in sweat glands
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

How is desiccated mucus treated in CF?

A
  • Physiotherapy to clear mucus
  • Mucolytic agents (N-Acetyl cysteine, DNase)
  • Increase in survival from <5 years to >40 years
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

How is infection treated in CF?

A
  • Prevents respiratory infections

- Aggressive early treatment with antibiotics

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

How is inflammation treated in CF?

A
  • Use of anti=inflammatories
17
Q

How are bronchiectasis, respiratory failure treated in CF?

A
  • Lung and heart/lung transplants
18
Q

Describe the new therapies in CF

A
  • Read through premature stop codon
  • Improve repair CFTR folding and trafficking
  • Potentiate CFTR channel activity
  • Activate alternate chloride channel
  • Inhibit ENaC activity
19
Q

How does Ivacaftor work- CFTR potentiator?

A
  • Class 3 mutation (defect in CFTR opening)
  • Oral medication daily
  • -> increases CFTR opening times from 5 to 50%
  • -> improves lung function
  • Cytochrome P450 substrate so potential for drug interaction
  • Long-term safety still being evaluated
  • Very expensive
20
Q

How does CF corrector Lumacaftor work?

A
  • Targets class 2 so more useful
  • Facilitates CFTR processing and cell surface expression
  • Increased Cl- transport 15% of normal
  • Phase 2 studies showed no clinical benefit of lumacaftor alone in ∆F508 patients
  • Combination of ivacaftor and lumacaftor gave a small improvement in FEC1
21
Q

What are some other CF correctors?

A
  • VX-661 structurally distinct from Lumacaftor
  • Appears to have better PK profile and fewer drug interaction ivacaftor
  • Phase 2 trials indicated modest FEV1 improvement in patients homozygous for ∆F508
22
Q

What are CFTR read-through agents? (hint: long names)

A
  • Aminoglycoside gentamicin can improve chloride transport but is associated with toxicity
  • Ataluren improved FEV1 in a subgroup of patients not receiving inhaled tobramycin maintenance therapy
23
Q

Describe gene replacement therapy in CF

A
  • Viral vector or liposome with gene for CFTR

- Delivered direct to airway epithelium

24
Q

What are the problems in gene replacement therapy?

A
  • Epithelial cells constantly replaces and excess mucus in airway impedes delivery
  • Viral vectors initiate an immune response
  • Response for adenovirus are not on apical surface of cell
  • Recent UK trials of a plasmid DNA-liposome complex stabilised lung function
25
Q

How can other ion channels be altered?

A
  • Amiloride- inhibits ENaC
  • Increase Cla activity by increasing ATP/UTP
    • ATP does not easily cross plasma membrane
    • Develop approaches to increase ATP
26
Q

Describe precision as a factor of therapeutic trials for CF patients

A
  • Variable responses to CFTR modulator therapy
  • Sweat chloride is considered a reliable biomarker but improvements in Cl- levels fo not predict clinical endpoints such as FEV1
  • Many disease causing mutations are rare- not possible to carry out randomised placebo-controlled trials in all patients
  • Better biomarkers needed